{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:41:46Z","timestamp":1792680106563,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Inflammatory bowel disease (IBD), comprising Crohn\u2019s disease and ulcerative colitis, is characterized by chronic intestinal inflammation and may be complicated by gastrointestinal infections. Among these,\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection (CDI) is relevant because of its association with worse outcomes and increased therapeutic needs. We aimed to evaluate the prevalence of enteric infections during IBD flares and to assess the long-term impact of CDI on disease management and treatment escalation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 102 IBD patients hospitalized for disease flares at a single tertiary care center between January 2020 and September 2024. All patients underwent stool testing for enteric pathogens. Clinical, laboratory, and treatment data were collected at baseline and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Gastrointestinal infections were detected in 19% of patients; CDI accounted for 58% of these. At 12 months after gastrointestinal infection, advanced therapy use was more frequent in gastrointestinal infection positive (GI+) patients (63% vs. 43%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.04). CDI+ patients had a significant increase in biologic use over time. Gastrointestinal infection positivity was independently associated with biologic use at 12 months (odds ratio\u2005=\u20053.5,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Recognizing gastrointestinal infection promptly and integrating infection history into therapeutic decision-making may improve patient outcomes by preventing severe disease progression and guiding timely escalation of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/meg.0000000000003296","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:25Z","timestamp":1792677625000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clostridioides difficile infection increases the need for using biologics in patients with inflammatory bowel diseases: a retrospective long-term study"],"prefix":"10.1097","author":[{"given":"Rocco","family":"Spagnuolo","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Guido Maria","family":"Scarlata","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Morano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Imoletti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Marascio","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Clinical Microbiology Unit, \u201cRenato Dulbecco\u201d University Hospital of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pantanella","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Clinical Microbiology Unit, \u201cRenato Dulbecco\u201d University Hospital of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Suraci","sequence":"additional","affiliation":[{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Marasco","sequence":"additional","affiliation":[{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Imeneo","sequence":"additional","affiliation":[{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Serapide","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, University \u201cMagna Graecia\u201d of Catanzaro, Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Trecarichi","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, University \u201cMagna Graecia\u201d of Catanzaro, Catanzaro"},{"name":"Department of Life Sciences, Health and Healthcare Professions, Link Campus University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, University \u201cMagna Graecia\u201d of Catanzaro, Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Quirino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Clinical Microbiology Unit, \u201cRenato Dulbecco\u201d University Hospital of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Abenavoli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Matera","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Clinical Microbiology Unit, \u201cRenato Dulbecco\u201d University Hospital of Catanzaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Luzza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro"},{"name":"Digestive Disease Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"R1-20261022","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease.","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"R2-20261022","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/antibiotics13080726","article-title":"Prevalence of enteric pathogens and antibiotic resistance: results of a six-year active surveillance study on patients admitted to a teaching hospital.","volume":"13","author":"Marascio","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"R3-20261022","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41395-018-0211-8","article-title":"Enteric infections are common in patients with flares of inflammatory bowel disease.","volume":"113","author":"Axelrad","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"R4-20261022","doi-asserted-by":"crossref","first-page":"i994","DOI":"10.1093\/ecco-jcc\/jjad212.0634","article-title":"Prevalence of gastrointestinal infections in ulcerative colitis patients assessed with QIASTAT-DX\u00ae gastrointestinal panel 2.","volume":"18","author":"Anolli","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R5-20261022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2010.03.025","article-title":"A review of mortality due to Clostridium difficile infection.","volume":"61","author":"Karas","year":"2010","journal-title":"J Infect"},{"key":"R6-20261022","doi-asserted-by":"crossref","first-page":"320","DOI":"10.15386\/mpr-2832","article-title":"Irritable bowel syndrome after Clostridioides difficile infection.","volume":"98","author":"Iacob","year":"2025","journal-title":"Med Pharm Rep"},{"key":"R7-20261022","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-145-10-200611210-00008","article-title":"Narrative review: the new epidemic of Clostridium difficile-associated enteric disease.","volume":"145","author":"Bartlett","year":"2006","journal-title":"Ann Intern Med"},{"key":"R8-20261022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrgastro.2010.190","article-title":"Clostridium difficile infection: epidemiology, risk factors and management.","volume":"8","author":"Ananthakrishnan","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R9-20261022","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease.","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R10-20261022","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.","volume":"22","author":"Crobach","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R11-20261022","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era.","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R12-20261022","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14309\/ajg.0000000000003076","article-title":"Diagnosis and management of Clostridioides difficile in inflammatory bowel disease.","volume":"120","author":"Vaughn","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R13-20261022","doi-asserted-by":"crossref","first-page":"11736","DOI":"10.3748\/wjg.v20.i33.11736","article-title":"Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review.","volume":"20","author":"Trifan","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R14-20261022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5217\/ir.2020.00045","article-title":"Management of Clostridioides difficile infection in patients with inflammatory bowel disease.","volume":"19","author":"Khanna","year":"2021","journal-title":"Intest Res"},{"key":"R15-20261022","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections.","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R16-20261022","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R17-20261022","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"R18-20261022","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R19-20261022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R20-20261022","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/antibiotics13080769","article-title":"Clostridioides difficile infection: use of inflammatory biomarkers and hemogram-derived ratios to predict mortality risk in hospitalized patients.","volume":"13","author":"Scarlata","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"R21-20261022","doi-asserted-by":"crossref","first-page":"100555","DOI":"10.4240\/wjgs.v17.i4.100555","article-title":"Association of Clostridium difficile infection with clinical outcomes of patients with inflammatory bowel disease: a meta-analysis.","volume":"17","author":"Qi","year":"2025","journal-title":"World J Gastrointest Surg"},{"key":"R22-20261022","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/medicina59111935","article-title":"Ultrasound prevalence and clinical features of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a real-life cross-sectional study.","volume":"59","author":"Abenavoli","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R23-20261022","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R24-20261022","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/cix669","article-title":"2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea.","volume":"65","author":"Shane","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R25-20261022","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10620-018-5330-y","article-title":"Comparison of multiplex gastrointestinal pathogen panel and conventional stool testing for evaluation of diarrhea in patients with inflammatory bowel diseases.","volume":"64","author":"Ahmad","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R26-20261022","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/biomedicines13071676","article-title":"Impact of biologics and proton pump inhibitors on gastrointestinal infection risk in inflammatory bowel disease patients: a retrospective analysis of pathogen-specific outcomes and treatment interactions.","volume":"13","author":"Njeim","year":"2025","journal-title":"Biomedicines"},{"key":"R27-20261022","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12876-025-03650-3","article-title":"Risk factors for Clostridioides difficile infection among patients diagnosed with inflammatory intestinal and rheumatological diseases in the biologic era.","volume":"25","author":"Mart\u00ednez-Lozano","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R28-20261022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ibd\/izy308","article-title":"Escalation of immunosuppressive therapy for inflammatory bowel disease is not associated with adverse outcomes after infection with Clostridium difficile.","volume":"25","author":"Lukin","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R29-20261022","article-title":"Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study.","volume":"19","author":"Noviello","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000003296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:28Z","timestamp":1792677628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MEG.0000000000003296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000003296","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}